越橘提取物通过调节大鼠代谢物和肠道菌群改善糖尿病肾病

Vaccinium myrtillus L. ameliorates diabetic nephropathy via modulating metabolites and gut microbiota in rats.

作者信息Xinxin Cao, Fan Yao, Wenxiu Liu, Yufang Wang, Zhen Zhang, Chongyang Zhang, Zhengqi Dong, Bin Zhang, Ruikun He, Xiaobo Sun
PMID40264677
发布时间2025-04-08
DOI10.3389/fphar.2025.1541947

实验完整度

包含体内动物模型(STZ/HFD诱导DN大鼠)和体外细胞模型(AGEs诱导足细胞损伤),并进行功能验证(生化指标、组织病理)和机制验证(Western blot、qPCR)。

主要模型

STZ/HFD诱导的糖尿病肾病大鼠模型 AGEs诱导的足细胞损伤模型(MPC-5足细胞)

重点核对

大鼠分组:正常对照组、模型组、恩格列净组(3.5 mg/kg)、VCE低(54 mg/kg)、中(162 mg/kg)、高(486 mg/kg)剂量组 给药方式:灌胃,每日一次,持续8周 AGEs处理浓度:200 μg/mL,处理24小时 VCE及花青素预处理浓度:VCE(1.625、3.125 μM),PGL(25、50 μM),MGL(25、50 μM),CAR(25、50 μM) 样本量:每组15只大鼠;代谢组学每组6只

摘要

Introduction: Diabetic nephropathy (DN), one of the serious complications in the diabetes, has a high mortality in the diabetic patients. Bilberry (Vaccinium myrtillus L.) have received much attention for their health benefits in alleviating metabolic diseases, which are rich in anthocyanins. However, the anti-DN ability of bilberry has not been fully studied. The aim of this study was to investigate the effect and mechanism of Vaccinium myrtillus L. extract (VCE) on diabetic nephropathy in vivo and in vitro.Methods: Streptozocin (STZ) combined with high fat induced DN model was established in rats. Biochemical indicators, histopathology, 16s third generation sequencing and serum metabolomics were used to evaluate the effects of VCE on DN. Subsequently, a cell model of advanced glycation end products (AGEs) induced podocyte injury was established to verify which compounds in VCE played the main anti-diabetic nephropathy function and the mechanism of action. Finally, in vitro experiments were conducted to verify the effect of characteristic metabolites screened by serum metabolomics on improving diabetic nephropathy.Results: Insulin resistance index, lipid metabolism, oxidative stress and inflammatory response indexes of DN rats were significantly improved after 8 weeks of VCE treatment. In addition, intake of VCE modulates gut microbiota composition and reverses the abundance of Lactobacillus, Bifidobacterium and Ruminococcus. Supplementation with VCE altered serum metabolite levels, including uridine and phenylacetylglycine. Pretreatment with VCE and its anthocyanins inhibited the expression of LDH, IL-6 and TNF-α, reduced the levels of p38-MAPK, IĸBα, IKKβ, and NF-κB in podocyte cells. In addition, pretreatment with serum metabolite uridine also reduced the expression of LDH and mitochondrial ROS, and inhibited cell apoptosis.Conclusion: Our findings suggest that the improvement of gut microbiota and metabolic function were related to the anti-DN potential of VCE, and the underlying mechanism may be related to the inhibition of MAPK/NF-κB signaling pathway.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
越橘提取物(VCE)是否能够改善糖尿病肾病(DN)及其作用机制。
核心机制
VCE通过抑制MAPK/NF-κB信号通路,减轻氧化应激和炎症反应,并调节肠道菌群和血清代谢物(如尿苷)来发挥肾脏保护作用。
主要证据
体内实验显示VCE改善DN大鼠的生化指标(GSP、INS、LDL等)和肾脏病理损伤,并调节肠道菌群(如乳酸杆菌、双歧杆菌、瘤胃球菌属)和血清代谢物(尿苷、苯乙酰甘氨酸);体外实验显示VCE及其花青素(PGL、MGL、CAR)抑制AGEs诱导的足细胞损伤、炎症反应和MAPK/NF-κB通路激活。
研究意义
研究表明VCE可能通过调节肠道菌群和代谢功能来延缓DN进展,并提示富含VCE的膳食干预可能对DN患者有益,为VCE治疗DN的临床试验提供依据。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

建立糖尿病肾病大鼠模型及分组给药

评估VCE对DN大鼠的干预效果。

SD大鼠高脂饮食4周后腹腔注射STZ(50 mg/kg)诱导DN模型,随机分为对照组、模型组、阳性药组(恩格列净3.5 mg/kg)和VCE低、中、高剂量组(54、162、486 mg/kg),每日灌胃给药8周。

2

检测生化指标和组织病理

评估VCE对DN大鼠糖脂代谢、肾功能、氧化应激和炎症的影响。

检测血清GLU、GSP、INS、LDL、HDL、CHOL、CML、CEL、LDH、MDA、SOD、GSH-Px、HO-1、CRP、IL-6、IL-1β等水平;检测尿液UA、uALB、NAG、KIM-1、β2-MG;肾组织H&E和PAS染色,免疫组化检测nephrin、podocin、4-HNE。

3

肠道菌群16S rRNA测序

分析VCE对DN大鼠肠道菌群组成和多样性的影响。

收集粪便样本,提取DNA,扩增16S rRNA V1-V9区,PacBio平台测序,分析菌群组成和多样性。

4

血清代谢组学分析

筛选VCE调节的差异代谢物。

对对照组、模型组和VCE高剂量组大鼠血清进行非靶向代谢组学分析,鉴定差异表达代谢物。

5

细胞实验验证VCE及花青素对AGEs诱导足细胞损伤的保护作用

验证VCE及其主要花青素对AGEs诱导的足细胞损伤的保护作用及机制。

MPC-5足细胞用AGEs(200 μg/mL)诱导损伤,分别用VCE、PGL、MGL、CAR预处理,检测细胞活力(CCK-8)、LDH释放、qPCR检测IL-6和TNF-α,Western blot检测MAPK/NF-κB通路蛋白。

6

验证血清代谢物尿苷的保护作用

验证代谢组学筛选的差异代谢物尿苷对AGEs诱导足细胞损伤的影响。

用尿苷(12.5-100 μM)预处理足细胞,检测细胞活力、LDH释放、线粒体ROS和细胞凋亡。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
链脲佐菌素----
恩格列净Shanghai Yuanye Biotechnology Co. LTD--
DMEM培养基Gibco6124275
胎牛血清GibcoA5256701
青霉素/链霉素Gibco15140-122
晚期糖基化终末产物Beijing Boaosen Biotechnology Co., LTDbs-1158P
低密度脂蛋白检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100020248
高密度脂蛋白检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100020238
葡萄糖检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100000240
肌酐检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100000320
尿素氮检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100020072
β2-微球蛋白检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100109070
尿酸检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100020110
尿微量白蛋白检测试剂盒Zhongsheng Beihang Biotechnology Co., LTD100109060
乳酸脱氢酶检测试剂盒Nanjing Jiancheng Bioengineering Research Institute Co. LTDA020-2-2
N-乙酰-β-D-氨基葡萄糖苷酶ELISA试剂盒Jiangsu Jingmei Biotechnology Co., LTD01724R1
肾损伤分子ELISA试剂盒Jiangsu Jingmei Biotechnology Co., LTD01943R1
抗p65 NF-κB抗体Proteintech10745-1-AP
抗磷酸化p65 NF-κB抗体Proteintech82335-1-RR
抗p38抗体Proteintech14064-1-AP
抗磷酸化p38抗体Proteintech28796-1-AP
抗IκBα抗体Proteintech10268-1-AP
抗IKKβ抗体Proteintech15649-1-AP
HSP90抗体Cell Signaling Technology, Inc.4874
线粒体红色荧光探针Beyotime BiotechnologyC1035
Hoechst 33342染色液Beyotime BiotechnologyC1027
MPC-5足细胞Shanghai Hongshun Biotechnology Co., LTD--
CCK-8试剂Dojindo--
Trizol试剂----
PrimeScript逆转录试剂盒TAKARA--
SYBR Premix Ex Taq IITAKARA--
Bio-Rad CFX-96实时荧光定量PCR仪Bio-Rad--
硝酸纤维素膜Millipore--
Image Lab软件Bio-Rad--
Mindray BS-420全自动生化分析仪Mindray--
Waldron DR-200BS酶标仪Waldron--
超高效液相色谱-串联质谱Waters/SCIEX--
Vanquish超高效液相色谱系统Thermo Fisher--
Orbitrap Q Exactive HF-X质谱仪Thermo Fisher--
E.Z.N.A.土壤DNA提取试剂盒Omega Bio-tek--
AxyPrep DNA凝胶回收试剂盒Axygen Biosciences--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型建立与分组
大鼠品系、性别、周龄、体重;高脂饮食诱导时间;STZ剂量和给药方式;分组、每组样本量;VCE剂量和给药途径
阅读提示:2.2 Animals treatments
给药方案
VCE剂量(54、162、486 mg/kg)、恩格列净剂量(3.5 mg/kg)、给药频率(每日一次)、给药时间(8周)
阅读提示:2.2 Animals treatments
生化指标检测
试剂盒品牌和货号、检测仪器、样品类型(血清/尿液)
阅读提示:2.3 Fasting blood glucose and biochemical marker assays
组织病理学
染色方法(H&E、PAS)、免疫组化抗体(nephrin、podocin、4-HNE)
阅读提示:2.4 H&E staining, PAS staining and immunohistochemical assays
肠道菌群测序
DNA提取试剂盒、扩增引物(27F/1492R)、测序平台(PacBio Sequel)、数据分析方法
阅读提示:2.5 Microbiota analysis by 16S rRNA sequencing
血清代谢组学
样本量(每组6只)、仪器(Vanquish UHPLC-Q Exactive HF-X)、数据处理软件
阅读提示:2.6 Serum metabolomics
细胞培养和处理
细胞系(MPC-5足细胞)、培养基(DMEM+10% FBS+1% P/S)、培养条件(37°C、5% CO2)、AGEs浓度(200 μg/mL)和处理时间(24h)
阅读提示:2.7 Cell culture and treatment
细胞活力检测
细胞接种密度(5×10^4/孔)、CCK-8孵育时间(2h)、检测波长(450nm)
阅读提示:2.8 Cell viability, LDH release assays and fluorescent staining
qPCR
RNA提取方法、逆转录试剂盒、qPCR试剂、引物序列(18S, IL-6, TNF-α)
阅读提示:2.9 Quantitative real-time PCR
Western blot
抗体(p65, p-p65, p38, p-p38, IκBα, IKKβ, HSP90)、分离胶浓度(10%)、转膜条件(300mA, 1h)
阅读提示:2.10 Western blot analysis